Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 145,407 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorder Clear all

Conditions: Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
Interventions: Vincristine, Sirolimus; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 31 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more

Conditions: Lumbar Disc Disease
Interventions: Autologous bone marrow aspirate injected intradiscal after microdiscectomy, Discectomy only; Procedure
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Temporal Lobe Epilepsy
Interventions: High-Impact Aerobic Exercise, Low-Impact Aerobic Exercise; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
Interventions: UltraMealPlus 360 (Medical food), Low-glycemic-load diet; Dietary Supplement · Other
Lead sponsor: MetaProteomics LLC; Industry
Eligibility: 20 Years to 75 Years · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Abdominal Aortic Aneurysm
Interventions: Endovascular Repair of the abdominal aorta, Cook Zenith Stent-Graft, Talent Stent-Graft; Procedure · Device
Lead sponsor: Center for Vascular Awareness, Albany, New York; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Albany, New York

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Overweight and Obesity
Interventions: "Eat Right Now" (ERN) mobile application; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: stereotactic radiosurgery, whole-brain radiation therapy; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 37
States / cities: Burlingame, California • Los Angeles, California • Newark, Delaware + 30 more

Conditions: Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System, Limbic Encephalitis
Interventions: IVIG; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Interventions: XO Genius; Dietary Supplement
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Infertility
Interventions: semi-quantitative pregnancy test; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Sacromento, California • Stanford, California • Chicago, Illinois

Conditions: Chronic Wound, Venous Leg Ulcer, Diabetic Foot Ulcer
Interventions: Bordered Five-Layer Foam Dressing, Hydropolymer Foam Dressing, Hydrocellular Multi-Layer Foam Dressing; Device
Lead sponsor: Molnlycke Health Care AB; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Castro Valley, California • San Francisco, California • Newark, New Jersey + 1 more

Conditions: Obesity
Interventions: Wellness Coaching for Families and Kids; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 2 Years to 8 Years
Enrollment: 6,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Type 1 Diabetes
Interventions: Pramlintide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuromuscular Diseases
Interventions: Oscillation and Lung Expansion (OLE) therapy; Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 5 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Psychological Stress
Interventions: Cognitive Behavioral Stress Management (CBSM) group intervention; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Epilepsy
Interventions: EpiPick simplified seizure classification algorithm; Diagnostic Test
Lead sponsor: Sándor Beniczky; Other
Eligibility: 10 Years to 120 Years
Enrollment: 240 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Koning Breast CT-guided Biopsy; Device
Lead sponsor: Koning Corporation; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Relapsed or Refractory Acute Myeloid Leukemia
Interventions: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes, Cyclophosphamide; Biological · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depression, Depressive Disorder, Metabolic Syndrome
Interventions: Exercise; Behavioral
Lead sponsor: California State University, San Marcos; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Diabetes Mellitus
Interventions: Pharmacist disease/medication management, Pharmacist-patient encounters, Pharmacist medication intensification and adherence support, Pharmacist communication with primary care physicians, Pharmacist documentation in electronic medical record, Health promoter-patient encounters in-person or by phone, Health promoter medication and lifestyle support, Health promoter communication with pharmacists; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 21 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcohol Dependence, Alcohol Drinking, Alcohol-Related Disorders, Alcoholism, Brain Mapping
Interventions: Not listed
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions: Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri

Conditions: Leukemia
Interventions: filgrastim, lintuzumab, arsenic trioxide, idarubicin, tretinoin; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

Injection of Autologous Bone Marrow Aspirate in Patients With Degenerative Disc Disease.

Exercise for Brain Regeneration in Epilepsy

Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome

Acute Technical Outcomes of the Talent Abdominal Aortic Aneurysm (AAA) Stent-Graft Versus Cook Zenith Stent-Graft

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

An App-based Mindfulness Intervention for Sexual Minority Women With a History of Early Life Adversities (ELA)

Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

The Impact of KETO5 XOGenius Beverage on Markers of Physiological and Neurocognitive Health

Exploring Semi-Quantitative Pregnancy Tests and Their Impact on Reproductive Health Service Provision

Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds

Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients

Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response

Validation Study of the Simplified Seizure Classification Algorithm

Koning Breast Computed Tomography Guided Biopsy

CD123 Redirected Autologous T Cells for AML

Does Antidepressant Use Blunt Adaptations to Exercise?

Health Promoters and Pharmacists in Diabetes Team Management

Characterization Imaging Instruments in Alcoholics and Non-Alcoholics

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia